These drugs are among the mainstays in the treatment of bacterial infections, and pathogen resistance to their action is a serious clinical problem, exacerbated by the possibility of switching from inducible to continuous enzyme production during antibiotic administration; classical beta-lactamase inhibitors (clavulanic acid and sulbactam) have no effect [29]. This evidence concerns the gene LACTB and bacterial infectious disease.